NEW YORK – Revel Health and Coriell Life Sciences (CLS) said on Tuesday that they have partnered to help Medicare Advantage members take advantage of DNA testing to determine prescription drug efficacy.
Using Revel Connect, Revel Health's health action platform, the partners will communicate and promote CLS's genetic testing offering to Medicare Advantage members. Revel Health and CLS launched the first wave of the program in June to reach more than 22,000 members.